OBJECTIVE
To investigate admission hyperglycemia effects on the sympathetic system and long-term prognosis in Takotsubo syndrome (TTS).
RESEARCH DESIGN AND METHODS
In patients with TTS and hyperglycemia (n = 28) versus normoglycemia (n = 48), serum norepinephrine and 123I-labeled metaiodobenzylguanidine (MIBG) cardiac scintigraphy were assessed. Heart failure (HF) occurrence and death events over 2 years were evaluated.
RESULTS
At hospitalization, those with hyperglycemia versus normoglycemia had higher levels of inflammatory markers and B-type natriuretic peptide and lower left ventricular ejection fraction. Glucose values correlated with norepinephrine levels (R2 = 0.39; P = 0.001). In 30 patients with TTS, 123I-MIBG cardiac scintigraphy showed lower late heart-to-mediastinum ratio values in the acute phase (P < 0.001) and at follow-up (P < 0.001) in those with hyperglycemia. Patients with hyperglycemia had higher rates of HF (P < 0.001) and death events (P < 0.05) after 24 months. In multivariate Cox regression analysis, hyperglycemia (P = 0.008), tumor necrosis factor-α (P = 0.001), and norepinephrine (P = 0.035) were independent predictors of HF events.
CONCLUSIONS
Patients with TTS and hyperglycemia exhibit sympathetic overactivity with a hyperglycemia-mediated proinflammatory pathway, which could cause worse prognosis during follow-up.
<b>OBJECTIVES</b>: To investigate admission hyperglycemia effects on the sympathetic
system and long-term prognosis in Takotsubo syndrome (TTS).
<p><b>RESEARCH DESIGN AND METHODS: </b>in TTS hyperglycemics (n=28) vs normoglycemics (n=48) serum
norepinephrine and 123I-MIBG
cardiac scintigraphy (123I-MIBGcS)
were assessed. Heart failure (HF) occurrence and deaths events over 2-years were
evaluated.</p>
<p><b>RESULTS: </b>At hospitalization, hyperglycemics vs
normoglycemics had higher levels of inflammatory markers, BNP and lower left
ventricle ejection fraction (LVEF). Glucose values correlated with
norepinephrine levels (R<sup>2</sup>=0.39, p=0.001). In 30 TTS patients, 123I-MIBGcS showed lower H/M<sub>late</sub> values<sub> </sub>in
the acute phase (p<0.001) and
at follow-up (p<0.001) in
hyperglycemic patients. Hyperglycemics had a higher rate of HF events
(p<0.001) and deaths (p<0.05) after 24-months. At multivariate Cox
Regression analysis, hyperglycemia (p=0.008), TNF-α (p=0.001) and norepinephrine (p=0.035) were independent
predictors of HF events.</p>
<p><b>CONCLUSIONS: </b>TTS hyperglycemic patients exhibit a sympathetic overactivity with a hyperglycemia-mediated pro-inflammatory
pathway which could cause a worse prognosis during follow-up.<b><br>
</b></p>
Background: In patients with type 2 diabetes mellitus (T2DM) the vaso-vagal syncope (VVS) recurrence could be due to the alteration of autonomic system function, evaluated by heart rate variability (HRV), and by 123I-metaiodobenzylguanidine (123I-mIBG) myocardial scintigraphy indexes: Heart to Mediastinum ratio (H/Mlate), and Washout rate (WR). The SGLT2-I could modulate/reduce autonomic dysfunction in T2DM patients with VVS. This effect could reduce the VVS recurrence in T2DM patients. Methods: In a prospective multicenter study, we studied a population of 607 T2DM patients affected by VVS, as SGLT2-I-users (n 161) vs. Non-SGLT2-I users (n 446). Thus, in SGLT2-I-users vs. Non-SGLT2-I users, we investigated the HRV and 123I-MIBG modifications and VVS recurrence at 12 months of follow-up. Results: At baseline, and follow-up end Non-SGLT2-I users vs. SGLT2-I-users over-expressed the inflammatory markers and norepinephrine, with worse glucose homeostasis and significant difference of HRV parameters, H/Mlate, and the WR (p<0.05). Non-SGLT2-I users vs. SGLT2-I-users had higher recurrence of all causes VVS, and of vasodepressor, and mixed VVS (p<0.05). The Cox regression analysis showed that the H/Mlate (0.710, CI 95% [0.481-0.985]; p 0.024), and SGLT2-I (0.550, CI 95% [0.324-0.934]; p 0.027) predicted all VVS recurrence. Conclusions: Non-SGLT2-I users vs. SGLT2-I-users had alterations of the autonomic nervous system, with a higher rate of VVS recurrence at 1 year of follow-up. The indexes of cardiac denervation predicted the VVS recurrence, while the SGLT2-I reduced the risk of VVS recurrence. Clinical trial registration number: NCT03717207.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.